InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
October 12, 2021

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in the latest episode of the “Stock2Me Podcast,” an IBN (InvestorBrandNetwork) solution to provide specialized content distribution via widespread syndication channels. Lexaria’s CEO and Chairman Chris Bunka joined the latest episode to discuss the company’s business model, his professional background and the team behind Lexaria, as well as the company’s recent transformative steps to position it for accelerated growth. “Our company kind of had a rebirth in January 2021. … We completed a 1-for-30 reverse stock split,” Bunka explained. “That was really hard, and just so you all know, I was the biggest shareholder. I am still the biggest shareholder. I took a big hit on my own holdings, but we had to do that to make the company attractive for future shareholders. … We got listed on Nasdaq in January and completed an $11 million financing. That was the biggest financing in the history of the company, and it transformed us. … We were able to step on the gas pedal and basically work on our research and development and our commercial studies at a 5-10x higher pace than anything we could do in the past. Therefore, this year, we’ve done more work than we did in the five years previous — all put together.”

To view the full press release, visit https://ibn.fm/OafXj

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).